

**Opportunity Title:** Drug Induced Liver Injury Mechanisms Fellowship

**Opportunity Reference Code:** FDA-CDER-2024-1388

**Organization** U.S. Food and Drug Administration (FDA)

**Reference Code** FDA-CDER-2024-1388

**How to Apply** *Connect with ORISE...on the GO!* Download the new ORISE GO mobile app in the [Apple App Store](#) or [Google Play Store](#) to help you stay engaged, connected, and informed during your ORISE experience and beyond!

A complete application consists of:

- An application
- Transcripts – [Click here for detailed information about acceptable transcripts](#)
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation

All documents must be in English or include an official English translation.

If you have questions, send an email to [ORISE.FDA.CDER@orau.org](mailto:ORISE.FDA.CDER@orau.org). Please include the reference code for this opportunity in your email.

**Application Deadline** 6/28/2024 3:00:00 PM Eastern Time Zone


**Description** \*Applications will be reviewed on a rolling basis

This project is in the Office of New Drugs (OND), Immediate Office (IO). This project will conduct regulatory research on drug induced liver injury (DILI) mechanisms using new approach methodologies (NAMs) such as micro physiological systems (MPS). We anticipate conducting experiments using multiple MPS platforms from different manufacturers and evaluating multiple drugs that have been shown to cause DILI via different mechanisms. This type of cross platform, cross laboratory research using the same set of drugs will be valuable in establishing best practices which will support the drafting of a planned guidance document, as well as to pave the way for the submission of qualification packages for MPS under the IStand program.

Under the guidance of the mentor, the participant will:

- learn how to search CDER database of nonclinical submissions to look for DILI in study reports.
- learn to search drug labels and published literature for clinical DILI information which will be added to data collected under #1
- learn to organize and analyze nonclinical and clinical data from multiple sources.
- learn how to use the information obtained to support the drafting of a guidance document.

The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and



**ORISE GO**

The ORISE GO mobile app helps you stay engaged, connected and informed during your ORISE experience – from application, to offer, through your appointment and even as an ORISE alum!

Visit ORISE GO [↗](#)

GET IT ON  
**Google Play**

Download on the  
**App Store**

**Opportunity Title:** Drug Induced Liver Injury Mechanisms Fellowship

**Opportunity Reference Code:** FDA-CDER-2024-1388

generic drugs. This work covers more than just medicines.

---

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. **The initial appointment is for one year**, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. **The appointment is full-time at FDA in the Silver Spring, Maryland, area.** Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

**FDA Ethics Requirements** If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see [FDA Ethics for Nonemployee Scientists](#).

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:

- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- The fact that research materials and laboratory notebooks are the property of the FDA;
- ORISE fellow's obligation to protect and not to further disclose or use non-public information.

**Qualifications** The qualified candidate should be pursuing a doctoral degree in one of the relevant fields, anticipated to be received by May 31, 2024.

**Eligibility Requirements**

- **Degree:** Doctoral Degree received within the last 60 months or anticipated to be received by 5/31/2024 12:00:00 AM.
- **Discipline(s):**

**Opportunity Title:** Drug Induced Liver Injury Mechanisms Fellowship

**Opportunity Reference Code:** FDA-CDER-2024-1388

- **Life Health and Medical Sciences** ([2](#) )

**Affirmation** I have lived in the United States for at least 36 out of the past 60 months.  
(36 months do not have to be consecutive.)

I have read the FDA Ethics Requirements.